Skip to main content


Comparative Effectiveness Research

Featured

Quiz
True or False: Acalabrutinib demonstrated favorable progression free survival and overall survival compared with standard first-line treatments for chronic lymphocytic leukemia.
Videos
Jonathan Rosenberg, MD, discusses results from a phase 3 trial comparing enfortumab vedotin and chemotherapy in locally…
Videos
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo…
Videos
Sagar Patel, MD, discusses utilization trends and survival outcomes among guideline-supported treatment options in…
Videos
Tomasz Beer, MD, discusses results from a network meta-analysis comparing the efficacy of enzalutamide vs apalutamide,…
Back to Top